Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Emiltatug Ledadotin (Emi-Le, XMT-1660)

Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)

Servier (registry sponsor Day One Biopharmaceuticals) · Phase 1/2 · Recruiting · Enrollment 360

NCT05377996

Catalyst Primary completion. 02.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Catalyst EMBLEM-1 first patients dosed. 10.19.2026. Company release; event occurred.

ArmPopulationDoseEstimandComparatorEfficacy
Emi-Le, ACC efficacy cohortR/M ACC, evaluable (n = 45)Phase 1 doses (not stated in source)Single armn/robjective response rate: 35.6%, ASCO 2026disease control rate: 82.2%, ASCO 2026median duration of response: 7.4 months, ASCO 2026
Emi-Le, post hoc aggressive subtypeACC with solid histology or high-grade transformation (n = 32, post hoc)Phase 1 doses (not stated in source)Single armn/robjective response rate: 46.9%, ASCO 2026; post hocmedian progression-free survival: 7.8 months, ASCO 2026; post hocmedian duration of response: 6.4 months, ASCO 2026; post hoc
Emi-Le, ACC safety cohortACC safety population (n = 48)Phase 1 doses (not stated in source)Single armn/rn/r
EMBLEM-1 pivotal Phase 2 cohortaggressive ACC (solid histology or high-grade transformation); primary endpoint ORR80 mg/m2, cap 160 mgSingle armn/rn/r